Subjective Cognitive Decline (SCD)
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programsCog Fun Ageing interventionN/A1 trial
Cog Fun Ageing interventionN/A1 trial
Active Trials
UNION therapeuticsDenmark - Hellerup
1 programMultidomain Intervention ProgramN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Jerusalem PharmaceuticalsCog Fun Ageing intervention
UNION therapeuticsMultidomain Intervention Program
Jerusalem PharmaceuticalsCog Fun Ageing intervention
Clinical Trials (3)
Total enrollment: 102 patients across 3 trials
Testing the Cog-Fun Aging Program for Older Adults With Subjective Cognitive Decline
Start: Nov 2024Est. completion: Jul 202527 patients
N/ACompleted
The Effectiveness of Interventions Targeting Self-Perception of Aging in Older Adults with Subjective Cognitive Decline
Start: Nov 2024Est. completion: Jun 202564 patients
N/AEnrolling By Invitation
Cog-Fun Ageing Participation-centered, Health Promotion for Older Adults
Start: Apr 2024Est. completion: Jul 202411 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.